tetano
Editor, Senior Moderator
Front Immunol
. 2022 Feb 11;13:790334.
doi: 10.3389/fimmu.2022.790334. eCollection 2022.
Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation
Makoto Miyara[SUP] 1 [/SUP], Melissa Saichi[SUP] 1 [/SUP], Delphine Sterlin[SUP] 1 2 [/SUP], François Anna[SUP] 3 4 [/SUP], Stéphane Marot[SUP] 5 [/SUP], Alexis Mathian[SUP] 1 6 [/SUP], Mo Atif[SUP] 1 [/SUP], Paul Quentric[SUP] 1 [/SUP], Audrey Mohr[SUP] 1 [/SUP], Laetitia Claër[SUP] 1 [/SUP], Christophe Parizot[SUP] 1 [/SUP], Karim Dorgham[SUP] 1 [/SUP], Hans Yssel[SUP] 1 [/SUP], Jehane Fadlallah[SUP] 1 6 [/SUP], Thibaut Chazal[SUP] 1 6 [/SUP], Julien Haroche[SUP] 1 6 [/SUP], Charles-Edouard Luyt[SUP] 7 8 [/SUP], Julien Mayaux[SUP] 9 [/SUP], Alexandra Beurton[SUP] 9 10 [/SUP], Neila Benameur[SUP] 11 [/SUP], David Boutolleau[SUP] 5 [/SUP], Sonia Burrel[SUP] 5 [/SUP], Sophia de Alba[SUP] 12 [/SUP], Sasi Mudumba[SUP] 12 [/SUP], Rick Hockett[SUP] 12 [/SUP], Cary Gunn[SUP] 12 [/SUP], Pierre Charneau[SUP] 3 4 [/SUP], Vincent Calvez[SUP] 5 [/SUP], Anne-Geneviève Marcelin[SUP] 5 [/SUP], Alain Combes[SUP] 7 8 [/SUP], Alexandre Demoule[SUP] 9 [/SUP], Zahir Amoura[SUP] 1 6 [/SUP], Guy Gorochov[SUP] 1 [/SUP]
Affiliations
Abstract
The capacity of pre-existing immunity to human common coronaviruses (HCoV) to cross-protect against de novo COVID-19is yet unknown. In this work, we studied the sera of 175 COVID-19 patients, 76 healthy donors and 3 intravenous immunoglobulins (IVIG) batches. We found that most COVID-19 patients developed anti-SARS-CoV-2 IgG antibodies before IgM. Moreover, the capacity of their IgGs to react to beta-HCoV, was present in the early sera of most patients before the appearance of anti-SARS-CoV-2 IgG. This implied that a recall-type antibody response was generated. In comparison, the patients that mounted an anti-SARS-COV2 IgM response, prior to IgG responses had lower titres of anti-beta-HCoV IgG antibodies. This indicated that pre-existing immunity to beta-HCoV was conducive to the generation of memory type responses to SARS-COV-2. Finally, we also found that pre-COVID-19-era sera and IVIG cross-reacted with SARS-CoV-2 antigens without neutralising SARS-CoV-2 infectivity in vitro. Put together, these results indicate that whilst pre-existing immunity to HCoV is responsible for recall-type IgG responses to SARS-CoV-2, it does not lead to cross-protection against COVID-19.
Keywords: COVID-19; IgA; IgG; coronaviral infection; humoral immune response.
. 2022 Feb 11;13:790334.
doi: 10.3389/fimmu.2022.790334. eCollection 2022.
Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation
Makoto Miyara[SUP] 1 [/SUP], Melissa Saichi[SUP] 1 [/SUP], Delphine Sterlin[SUP] 1 2 [/SUP], François Anna[SUP] 3 4 [/SUP], Stéphane Marot[SUP] 5 [/SUP], Alexis Mathian[SUP] 1 6 [/SUP], Mo Atif[SUP] 1 [/SUP], Paul Quentric[SUP] 1 [/SUP], Audrey Mohr[SUP] 1 [/SUP], Laetitia Claër[SUP] 1 [/SUP], Christophe Parizot[SUP] 1 [/SUP], Karim Dorgham[SUP] 1 [/SUP], Hans Yssel[SUP] 1 [/SUP], Jehane Fadlallah[SUP] 1 6 [/SUP], Thibaut Chazal[SUP] 1 6 [/SUP], Julien Haroche[SUP] 1 6 [/SUP], Charles-Edouard Luyt[SUP] 7 8 [/SUP], Julien Mayaux[SUP] 9 [/SUP], Alexandra Beurton[SUP] 9 10 [/SUP], Neila Benameur[SUP] 11 [/SUP], David Boutolleau[SUP] 5 [/SUP], Sonia Burrel[SUP] 5 [/SUP], Sophia de Alba[SUP] 12 [/SUP], Sasi Mudumba[SUP] 12 [/SUP], Rick Hockett[SUP] 12 [/SUP], Cary Gunn[SUP] 12 [/SUP], Pierre Charneau[SUP] 3 4 [/SUP], Vincent Calvez[SUP] 5 [/SUP], Anne-Geneviève Marcelin[SUP] 5 [/SUP], Alain Combes[SUP] 7 8 [/SUP], Alexandre Demoule[SUP] 9 [/SUP], Zahir Amoura[SUP] 1 6 [/SUP], Guy Gorochov[SUP] 1 [/SUP]
Affiliations
- PMID: 35222375
- PMCID: PMC8873934
- DOI: 10.3389/fimmu.2022.790334
Abstract
The capacity of pre-existing immunity to human common coronaviruses (HCoV) to cross-protect against de novo COVID-19is yet unknown. In this work, we studied the sera of 175 COVID-19 patients, 76 healthy donors and 3 intravenous immunoglobulins (IVIG) batches. We found that most COVID-19 patients developed anti-SARS-CoV-2 IgG antibodies before IgM. Moreover, the capacity of their IgGs to react to beta-HCoV, was present in the early sera of most patients before the appearance of anti-SARS-CoV-2 IgG. This implied that a recall-type antibody response was generated. In comparison, the patients that mounted an anti-SARS-COV2 IgM response, prior to IgG responses had lower titres of anti-beta-HCoV IgG antibodies. This indicated that pre-existing immunity to beta-HCoV was conducive to the generation of memory type responses to SARS-COV-2. Finally, we also found that pre-COVID-19-era sera and IVIG cross-reacted with SARS-CoV-2 antigens without neutralising SARS-CoV-2 infectivity in vitro. Put together, these results indicate that whilst pre-existing immunity to HCoV is responsible for recall-type IgG responses to SARS-CoV-2, it does not lead to cross-protection against COVID-19.
Keywords: COVID-19; IgA; IgG; coronaviral infection; humoral immune response.